5 results match your criteria: "University Health Network. m.urowitz@utoronto.ca.[Affiliation]"
Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?
J Rheumatol
September 2020
From the Centre for Prognosis Studies in Rheumatic Diseases, Toronto Lupus Clinic, University Health Network, Toronto, Ontario, Canada.
Objective: Advanced chronic kidney disease (CKD) carries an increased risk for progression to endstage renal disease (ESRD). We aimed to determine the rate of progression and the factors that drive the decline of renal function in lupus nephritis (LN).
Methods: Patients with advanced LN-related CKD were identified from our longterm longitudinal cohort.
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?
J Rheumatol
January 2019
From the Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, University Health Network; Cardiology Department, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
Objective: Cardiac involvement in systemic lupus erythematosus (SLE) is often undiagnosed in its early phases. Specific heart biomarkers may identify patients at risk. We sought to investigate the prevalence and associated factors for such biomarkers in SLE.
View Article and Find Full Text PDFMonophasic Disease Course in Systemic Lupus Erythematosus.
J Rheumatol
August 2018
From the Centre for Prognosis Studies in Rheumatic Diseases, Toronto Lupus Clinic, University Health Network, Toronto, Ontario, Canada.
Objective: Disease course in systemic lupus erythematosus (SLE) is primarily relapsing-remitting. Long quiescent and chronically active patterns are less frequent. We recently described an atypical "monophasic" course in a small number of patients.
View Article and Find Full Text PDFEvolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study.
J Rheumatol
December 2017
From the Centre for Prognosis Studies in Rheumatic Diseases, Toronto Lupus Clinic, University Health Network, Toronto, Ontario, Canada.
Objective: We previously reported the effect of certain factors on cardiovascular disease (CVD) in 250 women with systemic lupus erythematosus (SLE) followed for 8 years. The aim of this study was to delineate their evolution after 15 years of followup.
Methods: There were 210 women with SLE and 138 age-matched healthy women available for analysis after 15 years.
Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.
J Rheumatol
March 2016
From the Centre for Prognosis Studies in Rheumatic Diseases, University of Toronto Lupus Clinic, University Health Network, Toronto, Ontario, Canada.K. Tselios, MD, PhD, Centre for Prognosis Studies in Rheumatic Diseases, University of Toronto Lupus Clinic, University Health Network; D.D. Gladman, MD, FCRPC, Centre for Prognosis Studies in Rheumatic Diseases, University of Toronto Lupus Clinic, University Health Network; J. Su, MB, BSc, Centre for Prognosis Studies in Rheumatic Diseases, University of Toronto Lupus Clinic, University Health Network; M.B. Urowitz, MD, FRCPC, Centre for Prognosis Studies in Rheumatic Diseases, University of Toronto Lupus Clinic, University Health Network.
Objective: Mycophenolate mofetil (MMF), along with corticosteroids, is considered as the standard of care in lupus nephritis (LN); however, little is known regarding its efficacy in extrarenal manifestations of systemic lupus erythematosus (SLE). We aimed to determine its effectiveness in nonrenal SLE.
Methods: One hundred seventy-seven patients with SLE were enrolled; 105 for whom MMF was introduced for active LN (mean age 35.